Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Report 2022: A Market of Over $34 Billion in 2026

0

company logo

Global Apiss HP (High Power) Market

Global Apiss HP (High Power) Market

Global Apiss HP (High Power) Market

Dublin, June 20, 2022 (GLOBE NEWSWIRE) — The “Global HP (High Potency) API Market Report 2022: By Type, By Synthesis, By Therapeutics” report has been added to from ResearchAndMarkets.com offer.

The global HP (High Potency) API market is expected to grow from $22.61 billion in 2021 to $24.53 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The market is expected to reach $34.04 billion in 2026 at a CAGR of 8.5%.

The major players in the High Power API (HPAPI) market are Eli Lily and Company; Novartis SA; Bristol-Myers Squibb Company; Roche Diagnostics Ltd; Sanofi

The High Potency API (HPAPI) market consists of the sale of high potency active pharmaceutical ingredients and related services. High potency APIs are extremely effective in pharmacologically active ingredients. These are very specific in their action and offer significant efficacy even at low daily therapeutic doses. HPAPIs are used in high potency drug formulations, due to their ability to target specific disease cells, including cancer cells.

The main types of HP (High Potency) APIs are Innovative HPAPIs and Generic HPAPIs. The different types of synthesis include synthetic HPAPI and biotech HPAPI which are used for therapeutic applications such as oncology, hormonal disorders, glaucoma and other therapeutic applications (respiratory disorders, CVD, diabetes, cosmetology and erectile dysfunction). Glaucoma is a group of eye diseases that affect the optic nerve, which is essential for good vision.

North America was the largest region in the High Power API (HPAPI) market in 2021. The Middle East is expected to be the largest growing region during the forecast period. Regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Rising number of cancer cases coupled with increasing sales of anti-cancer drugs has contributed to the growth of the high potency API market. Rising incidence of cancer is driving rise in R&D on anti-cancer drugs which in turn is propelling the demand for high potency API market.

According to the World Health Organization’s International Agency for Research on Cancer (IARC) report, the cancer burden is expected to increase by 29.5 million new cases and 16.4 million deaths by 2040, in the world. In addition, 70% of cancer deaths occur in middle and low income countries. Hence, the rising incidence of cancer cases is expected to increase the high potency API market revenue.

High investment requirements are expected to restrain the growth of the market over the next few years. High potency APIs are cytotoxic, which is harmful to human cells. Additionally, they come with significant handling challenges, including the need for specialized equipment to avoid cross-contamination, product protection, and to ensure environmental and operator safety.

Additionally, the requirement for proper process design and ever-changing technologies and industry standards, specialized containment facilities to facilitate employee safety require tremendous financial support. Hence, large investment requirement is a major challenge for the growth of high power API market.

Companies operating in the high power API market are focusing on strategies such as expansion of production facilities and mergers and acquisitions to maintain their position in the competitive business environment.

HP API (High Power) Market Competitive Landscape and Company Profiles

  • Eli Lily and company

  • Novartis AG

  • Bristol-Myers Squibb Company

  • Roche Diagnostics Ltd.

  • Sanofi

  • Hospira Inc.

  • BASF SE

  • Covidien plc.

  • Boehringer Ingelheim GmbH

  • Merck & Co Inc.

  • Sigma Aldrich Corporation

  • Bayer AG

  • Carbogen Amcis AG

  • lonza

  • Teva Pharmaceutical Industries Ltd.

  • Pfizer Inc.

  • Mylan Inc.

  • AbbVie

  • AstraZeneca plc.

  • GlaxoSmithKline plc.

Main topics covered:

1. Summary

2. HP (High Power) API Market Features

3. HP API (High Power) Market Trends and Strategies

4. Impact of COVID-19 on HP APIs (High Power)

5. HP API (High Power) Market Size and Growth
5.1. Global HP API (High Power) Historic Market, 2016-2021, USD Billion
5.1.1. Market Drivers
5.1.2. Market Constraints
5.2. Global HP API (High Power) Forecast Market, 2021-2026F, 2031F, Billion USD
5.2.1. Market Drivers
5.2.2. Market Constraints

6. HP API (High Power) Market Segmentation
6.1. Global HP API (High Power) Market, Segmentation by Type, History & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

  • Innovative HPAPI

  • Generic HPAPI

6.2. Global HP API (High Power) Market, Segmentation by Synthesis Type, History & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

  • Synthetic HPAPI

  • HPAPI Biotechnology

6.3. Global HP API (High Potency) Market, Segmentation by Therapeutic Application, History & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

  • Oncology

  • Hormonal disorder

  • Glaucoma

  • Other therapeutic applications (respiratory disorders, cardiovascular diseases, diabetes, cosmetology and erectile dysfunction)

7. HP (High Power) API Market Regional and Country Analysis
7.1. Global HP API (High Power) Market Split by Region, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion
7.2. Global HP API (High Power) Market, Split by Country, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

For more information on this report, visit https://www.researchandmarkets.com/r/ybnh2q

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Share.

Comments are closed.